Welcome to our dedicated page for Novabay Pharma news (Ticker: NBY), a resource for investors and traders seeking the latest updates and insights on Novabay Pharma stock.
NovaBay Pharmaceuticals (NBY) delivers innovative non-antibiotic anti-infectives for ophthalmic care, wound management, and dermatological conditions. This page provides investors and healthcare professionals with timely updates on the company’s scientific advancements, regulatory milestones, and market strategies.
Access consolidated news about NBY’s Neutrox™ product line, including Avenova for chronic eye conditions, and developments in its Aganocide® compound research. Stay informed about financial disclosures, partnership announcements, and clinical trial outcomes through verified press releases and analysis.
Key updates include FDA submissions, international distribution expansions, and peer-reviewed study results. Our repository ensures efficient tracking of NovaBay’s progress in addressing antibiotic resistance challenges through its patented antimicrobial technologies.
Bookmark this page for direct access to NBY’s latest corporate communications. Check regularly for insights into commercialization efforts and research breakthroughs shaping the future of non-antibiotic therapies.
NovaBay Pharmaceuticals announced the approval of all proposals at its 2024 Annual Meeting, including a 1-for-35 reverse stock split. This decision aims to align with the NYSE American's listing standards and enhance stock marketability and liquidity. The reverse stock split will be effective on May 30, 2024, and shares will trade on a split-adjusted basis from May 31, 2024.
Additionally, NovaBay received a notice from NYSE American regarding non-compliance with stockholders’ equity requirements. They have until October 18, 2025, to meet these standards or face potential delisting. The company's recent financial statements included a going concern notice, highlighting ongoing financial challenges.
NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) introduces an expanded line of Avenova product bundles to address individualized relief from dry eye symptoms. The U.S. market for dry eye treatment is projected to reach $4.86 billion by 2030, with approximately 16 million Americans suffering from dry eye disease. The new Avenova bundles align with optometrists' recommendations for personalized treatment beyond artificial tears, offering easy, affordable, and effective solutions for managing dry eye symptoms.
NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) reported a 13% increase in net product sales driven by higher Avenova®-branded product sales through online channels and branded wound care products. Sales and marketing expenses decreased by 15%, with record sales for Avenova products on Amazon.com. The company remains focused on the eyecare market with efficient digital marketing programs aimed at expanding its customer base.
Financially, product sales for Q1 2024 were $2.6 million, a 13% increase from the prior year, driven by online sales. Gross margin remained stable at 68%. Sales and marketing expenses decreased by 15%, while G&A expenses and R&D expenses saw increases. The company reported a net loss attributable to common stockholders of $3.6 million for Q1 2024.
NovaBay Pharmaceuticals, Inc. (NBY) reports record sales of Avenova-branded products on Amazon.com in April 2024, with a 20% increase from the previous year. The company attributes the success to enhanced marketing programs and the high quality of its products. The U.S. dry eye disease market is projected to reach nearly $5 billion by 2030, indicating potential for further growth.
NovaBay Pharmaceuticals, Inc. (NBY) will release financial results for the first quarter ending March 31, 2024, on May 9, 2024, after the market closes. The company will host an investment community conference call at 4:30 p.m. Eastern time on the same day. Participants can pre-register to receive conference call details or join live by dialing in. A replay will be available after the call.
FAQ
What is the current stock price of Novabay Pharma (NBY)?
What is the market cap of Novabay Pharma (NBY)?
